Moxibustion in Osteoarthritis of the Knee

Phase 3

Completed

• Conditions: Knee Osteoarthritis
• Interventions: Other: real moxibustion; Drug: diclofenac sodium gel; Drug: placebo gel; Other: sham moxibustion

• Registration Number: NCT02769572
• Lead Sponsor: Chengdu University of Traditional Chinese Medicine

Brief Summary

This is a multicenter , double-blinded, double-dummy, randomized controlled clinical trial to evaluate the efficacy of moxibustion for osteoarthritis of the knee.

Detailed Description

Aim: To evaluate the effectiveness of moxibustion treatment for patients with osteoarthritis of the knee, with respect to relieving pain, improving the dysfunction and improving their quality of life as well.

Design: A multicentre, double-blinded, double-dummy, randomized controlled clinical study will be performed in China. Eligible participants will be randomly assigned to moxibustion group (real moxibustion plus placebo gel) and the control group (diclofenac sodium gel plus sham moxibustion) with a 1:1 allocation ratio. Participants in both groups will receive 12 sessions of real/sham moxibustion in 4 weeks at 3 acupoints (ST35, EX-LE4, ST36 ). Either diclofenac sodium gel or placebo gel will be applied 4 g per knee 4 times daily for 4 weeks. The whole study period is 13 weeks, with a 1-week run-in period, 4-week treatment phase, and 8-week follow-up phase. The primary outcome measure will be the change of the global scale of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at the end of the course. The secondary outcomes include the change of other subscales (pain, stiffness, and function) of WOMAC, Visual Analogue scale (VAS) and Patient Global Assessment (PGA). Safety will be assessed at every visit.

Study Timeline

• Study Start: 2016-05
• Study First Submitted: 2016-05-10
• Study First Submitted QC: 2016-05-10
• Study First Posted: 2016-05-11
• Primary Completion: 2019-06
• Study Completion: 2019-06
• Status Verified: 2020-02
• Last Update Submitted: 2020-02-13
• Last Update Posted: 2020-02-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 144

Inclusion Criteria

• Male or female, aged between 40 and 75 years, with knee osteoarthritis diagnosed according to American College of Rheumatology criteria
• Radiologic confirmation of osteoarthritis in 1 or both knees (Kellgren-Lawrence score 2 or 3)
• Had knee pain in one or both knee(s) of longer than 3 months'duration
• The average severity of knee pain at least 3 points on a10-point of visual analogue scale(VAS)
• Never experienced moxibustion before this trial
• Participants who are willing to comply with our study protocol
• Participants who agree to sign the consent form

Exclusion Criteria

• Subjects with serious diseases including cancer, uncontrolled hypertension, diabetes mellitus requiring insulin injection, life-threatening cardiovascular or neurological events, chronic respiratory disease, a haemorrhagic disorder and serious mental diseases
• Subjects had pain in the knee may caused by inflammatory, malignant, autoimmune disease or traumatic injury;
• Subjects received knee replacement surgery for the affected knee
• Subjects received knee arthroscopy within the past year, steroid or hyaluronic acid injection in the knee joints within the previous 3 months
• Subject who currently participate in another clinical trial
• Subjects received physiotherapy or other treatments for osteoarthritis knee pain (with the exception of non-steroidal anti-inflammatory drugs) during the previous 4 weeks;

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
real moxibustion plus placebo gel	real moxibustion	In subjects with osteoarthritis of the knee
real moxibustion plus placebo gel	placebo gel	In subjects with osteoarthritis of the knee
diclofenac sodium gel plus sham moxibustion	diclofenac sodium gel	In subjects with osteoarthritis of the knee
diclofenac sodium gel plus sham moxibustion	sham moxibustion	In subjects with osteoarthritis of the knee

Primary Outcome Measures

Name	Time	Method
The change of the global scale of the Western Ontario and McMaster Osteoarthritis Index (WOMAC)	4 weeks from baseline

Secondary Outcome Measures

Name	Time	Method
The changes from baseline to 2, 4, 8,12 weeks in the WOMAC subscales (pain, stiffness, and function)	at baseline(0 week), 2 weeks, 4weeks, 8 weeks and 12 weeks later after allocation
The change of Patient global assessment score	2 weeks, 4weeks, 8 weeks and 12 weeks later after allocation
The change from baseline to 2, 4, 8,12 weeks in Visual Analogue Scale for the pain intensity.	at baseline(0 week), 2 weeks, 4weeks, 8 weeks and 12 weeks later after allocation